Form 10-Q · Quarterly report
Boston Scientific 10-Q, filed Nov 2, 2026
- Filed
- CIK
- 0000885725
- Accession no.
- 0000885725-26-000070
Summary
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5%, and net income attributable to common stockholders of $582 million, down 22.9%, after an August 2026 cybersecurity incident disrupted manufacturing and order fulfillment and materially hurt results. For the first nine months of 2026, net sales rose 6.7% to $15.784 billion and net income rose 27.1% to $2.830 billion.
Key points
- Third-quarter 2026 reported net sales rose 1.5% to $5.138 billion, while reported net income attributable to common stockholders fell 22.9% to $582 million.
- First-nine-month 2026 reported net sales rose 6.7% to $15.784 billion and reported net income attributable to common stockholders rose 27.1% to $2.830 billion.
- An August 2026 cybersecurity incident caused a global disruption to operations, affecting manufacturing, order processing, and shipping, and materially impacted third-quarter financial results.
- Third-quarter growth was driven by Interventional Cardiology and Vascular Therapies, offset by cybersecurity disruptions, increased electrophysiology competition, and a deceleration in the left atrial appendage closure market affecting WATCHMAN procedures.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION Executive Summary The following section describes some of our financial highlights and trends on a consolidated basis. For additional information on our business units and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. (in millions, except percentages and per share data) Three Months Ended September 30, 2026 versus 2025 2026 versus 2025 2026 2025 $ % Reported net sales $ 5,138 $ 5,065 $ 74 1.5 % Reported net income (loss) attributable to Boston Scientific common stockholders 582 755 (173) (22.9) % Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measure) 1,063 1,124 (62)…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.